Nuwellis, Inc. (NUWE)
| Market Cap | 1.85M -56.1% |
| Revenue (ttm) | 8.77M -0.2% |
| Net Income | -18.84M |
| EPS | -15.93 |
| Shares Out | 2.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 286,506 |
| Open | 0.7300 |
| Previous Close | 0.7737 |
| Day's Range | 0.7000 - 0.7992 |
| 52-Week Range | 0.7000 - 39.0390 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Au... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsNews
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Nuwellis files to sell 4.85M shares of common stock, warrants
Ladenburg Thalmann is acting as exclusive placement agent.
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Nuwellis completes Aquadex SmartFlow System pre-submission meeting with the FDA
Nuwellis (NUWE) announced the completion of a recent pre-submission meeting with the FDA regarding the proposed label expansion of the Aquadex SmartFlow System to support pediatric patients weighing 5...
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
Proposal would extend treatment access to pediatric patients weighing 5 kg and above Proposal would extend treatment access to pediatric patients weighing 5 kg and above
Nuwellis Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth, improved gross margin, and a strengthened leadership team. Pediatrics now accounts for half of U.S. revenue, and a strategic acquisition expands the product portfolio. Cash burn reduction and disciplined capital allocation remain priorities.
Nuwellis Earnings release: Q1 2026
Nuwellis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nuwellis Quarterly report: Q1 2026
Nuwellis has published its Q1 2026 quarterly earnings report on May 12, 2026.
Nuwellis, Inc. Announces First Quarter 2026 Financial Results
MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported fin...
Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will ...
Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting
Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure Poster present...
Nuwellis gets notice of allowance from USPTO for lumen midline catheter
Nuwellis (NUWE) announced that the U.S. Patent and Trademark Office, or USPTO, has issued a notice of allowance for a new patent covering its novel dual lumen midline catheter technology…
Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology
MINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that t...
Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth ...
Nuwellis Announces Aquadex Software Update
MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software up...
Nuwellis announces return of three former team members
Nuwellis (NUWE) announces the return of three former team members: Liby Cielo, Principal Account Manager; Meredith Stein, Senior Clinical Education Specialist; and Scott Campbell, Area Vice President,...
Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the re...
Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has...
Nuwellis expands commercial footprint with new South Texas territory
Nuwellis (NUWE) announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets. By establishing a…
Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region Strategic expansion of field coverage enhances hospital engagement and inc...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals Pediatric footprint expands to 47 centers nationwide, including six of the nation's top ...
Nuwellis completes acquisition of Rendiatech
Nuwellis (NUWE) completed its acquisition of Rendiatech, an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill pa...
Nuwellis Completes Acquisition of Rendiatech
MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced ...